PriceTargets.com logo

bluebird bio - BLUE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $49.14
  • Forecasted Upside: 478.15%
  • Number of Analysts: 10
  • Breakdown:
  • 2 Sell Ratings
  • 6 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.50 As of 12/20/2024 06:45 PM ET
▼ -0.73 (-7.91%)

This chart shows the closing price for BLUE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New bluebird bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLUE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLUE

Analyst Price Target is $49.14
▲ +478.15% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for bluebird bio in the last 3 months. The average price target is $49.14, with a high forecast of $120.00 and a low forecast of $10.00. The average price target represents a 478.15% upside from the last price of $8.50.

This chart shows the closing price for BLUE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 contributing investment analysts is to hold stock in bluebird bio. This rating has held steady since March 2023, when it changed from a Reduce consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 2 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 2 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$80.00 ➝ $80.00
11/15/2024BarclaysLower TargetOverweight ➝ Overweight$80.00 ➝ $40.00
11/15/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
11/15/2024Bank of AmericaDowngradeBuy ➝ Neutral$60.00 ➝ $10.00
9/25/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$60.00 ➝ $40.00
9/16/2024Cantor FitzgeraldReiterated RatingNeutral
8/15/2024Bank of AmericaLower TargetBuy ➝ Buy$80.00 ➝ $60.00
8/15/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$80.00 ➝ $80.00
8/15/2024BarclaysLower TargetOverweight ➝ Overweight$160.00 ➝ $80.00
8/15/2024Robert W. BairdLower TargetOutperform ➝ Outperform$140.00 ➝ $120.00
8/15/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
3/27/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$120.00
3/27/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$80.00 ➝ $60.00
3/19/2024WedbushLower TargetNeutral ➝ Neutral$34.40 ➝ $33.60
3/5/2024HSBCLower TargetReduce ➝ Reduce$46.20 ➝ $20.40
1/9/2024William BlairReiterated RatingMarket Perform
1/8/2024WedbushReiterated RatingNeutral$60.00
12/21/2023Bank of AmericaLower TargetBuy ➝ Buy$240.00 ➝ $100.00
12/15/2023Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$160.00 ➝ $100.00
12/12/2023Robert W. BairdLower TargetOutperform ➝ Outperform$200.00 ➝ $140.00
12/11/2023HSBCDowngradeHold ➝ Reduce
12/11/2023Bank of AmericaBoost TargetBuy ➝ Buy$220.00 ➝ $240.00
12/8/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$60.00 ➝ $140.00
11/8/2023Raymond JamesBoost TargetOutperform ➝ Outperform$200.00 ➝ $260.00
11/7/2023WedbushReiterated RatingNeutral$140.00 ➝ $100.00
10/30/2023WedbushReiterated RatingNeutral$140.00
10/17/2023Cantor FitzgeraldInitiated CoverageNeutral
9/6/2023HSBCInitiated CoverageBuy$84.20
8/8/2023WedbushReiterated RatingNeutral$140.00
7/19/2023Bank of AmericaUpgradeNeutral ➝ Buy$120.00 ➝ $200.00
6/1/2023BarclaysUpgradeEqual Weight ➝ Overweight$140.00 ➝ $160.00
4/28/2023JPMorgan Chase & Co.Initiated CoverageOverweight$140.00
4/3/2023Morgan StanleyLower TargetUnderweight$80.00 ➝ $60.00
3/30/2023Royal Bank of CanadaReiterated RatingSector Perform$160.00
3/30/2023Bank of AmericaLower TargetNeutral$160.00 ➝ $120.00
3/22/2023William BlairReiterated RatingMarket Perform
3/6/2023Robert W. BairdInitiated CoverageOutperform$200.00
1/24/2023Morgan StanleyBoost TargetUnderweight$60.00 ➝ $80.00
1/23/2023Leerink PartnersLower TargetMarket Perform$180.00 ➝ $160.00
1/6/2023Leerink PartnersBoost TargetMarket Perform$160.00 ➝ $180.00
11/8/2022Royal Bank of CanadaLower TargetSector Perform$160.00
9/20/2022Raymond JamesBoost TargetOutperform$160.00 ➝ $200.00
8/19/2022The Goldman Sachs GroupBoost TargetSell$40.00 ➝ $60.00
8/18/2022Leerink PartnersBoost TargetMarket Perform$160.00 ➝ $200.00
8/5/2022BarclaysUpgradeUnderweight ➝ Equal Weight$60.00 ➝ $100.00
8/2/2022Raymond JamesUpgradeMarket Perform ➝ Outperform$160.00
5/17/2022Morgan StanleyLower TargetUnderweight$60.00
5/10/2022WedbushLower TargetNeutral$200.00 ➝ $160.00
5/10/2022BarclaysLower Target$80.00 ➝ $60.00
4/6/2022Leerink PartnersLower TargetMarket Perform$200.00 ➝ $160.00
4/6/2022CowenDowngradeOutperform ➝ Market Perform
3/8/2022Wells Fargo & CompanyLower TargetEqual Weight$240.00 ➝ $160.00
3/7/2022Morgan StanleyLower TargetUnderweight$120.00 ➝ $100.00
3/7/2022Leerink PartnersLower TargetMarket Perform$220.00 ➝ $200.00
3/7/2022BarclaysDowngradeEqual Weight ➝ Underweight$260.00 ➝ $80.00
1/6/2022Morgan StanleyLower TargetUnderweight$220.00 ➝ $200.00
1/3/2022The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
12/23/2021Leerink PartnersReiterated RatingHold
11/12/2021Berenberg BankReiterated RatingHold$220.00
11/12/2021BMO Capital MarketsLower TargetMarket Perform$420.00 ➝ $260.00
11/8/2021WedbushLower TargetNeutral$440.00 ➝ $220.00
11/8/2021Royal Bank of CanadaLower TargetNeutral ➝ Sector Perform$520.00 ➝ $280.00
11/8/2021Wells Fargo & CompanyLower TargetEqual Weight$500.00 ➝ $320.00
11/8/2021BarclaysLower TargetEqual Weight$400.00 ➝ $260.00
11/8/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$460.00 ➝ $200.00
11/8/2021Morgan StanleyDowngradeEqual Weight ➝ Underweight$220.00
9/22/2021MizuhoLower TargetBuy$580.00 ➝ $460.00
8/10/2021William BlairInitiated CoverageMarket Perform
8/10/2021BMO Capital MarketsLower TargetMarket Perform$580.00 ➝ $420.00
8/10/2021Bank of AmericaLower TargetNeutral$820.00 ➝ $440.00
8/10/2021MizuhoLower TargetBuy$1,400.00 ➝ $580.00
8/10/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$1,260.00 ➝ $460.00
8/10/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$1,200.00 ➝ $500.00
8/9/2021Stifel NicolausLower TargetHold$620.00 ➝ $360.00
8/9/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$1,280.00 ➝ $400.00
8/1/2021Leerink PartnersReiterated RatingBuy
7/16/2021Morgan StanleyLower TargetEqual Weight$720.00 ➝ $700.00
7/1/2021Berenberg BankDowngradeBuy ➝ Hold$700.00
6/15/2021OppenheimerReiterated RatingHold
6/10/2021Leerink PartnersInitiated CoverageBuy
4/21/2021BMO Capital MarketsLower TargetMarket Perform$700.00 ➝ $620.00
4/19/2021Morgan StanleyLower TargetEqual Weight$900.00 ➝ $720.00
3/29/2021Piper SandlerBoost Target$600.00 ➝ $700.00
3/29/2021Jefferies Financial GroupReiterated RatingBuy
3/29/2021Leerink PartnersBoost TargetOutperform$1,380.00 ➝ $1,440.00
3/29/2021BMO Capital MarketsBoost TargetMarket Perform$620.00 ➝ $700.00
3/28/2021OppenheimerReiterated RatingHold
3/14/2021Leerink PartnersReiterated RatingBuy
3/10/2021Stifel NicolausBoost Target$520.00 ➝ $620.00
3/10/2021MizuhoUpgradeNeutral ➝ Buy$680.00 ➝ $1,380.00
3/2/2021Morgan StanleyLower TargetEqual Weight$1,000.00 ➝ $900.00
2/24/2021BarclaysLower TargetEqual Weight$620.00 ➝ $540.00
2/17/2021BMO Capital MarketsBoost TargetMarket Perform$720.00 ➝ $1,120.00
2/17/2021Stifel NicolausLower TargetHold$960.00 ➝ $700.00
2/17/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
2/17/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$1,520.00 ➝ $780.00
2/16/2021OppenheimerDowngradeOutperform ➝ Market Perform
2/16/2021Bank of AmericaDowngradeBuy ➝ Neutral
2/16/2021WedbushDowngradeOutperform ➝ Neutral
2/16/2021MizuhoDowngradeBuy ➝ Neutral
2/16/2021Piper SandlerLower TargetNeutral$1,100.00 ➝ $700.00
2/16/2021William BlairDowngradeOutperform ➝ Market Perform
12/9/2020Maxim GroupDowngradeBuy ➝ Hold
12/7/2020MizuhoReiterated RatingBuy
11/11/2020Berenberg BankInitiated CoverageBuy$1,280.00
11/11/2020Morgan StanleyLower TargetEqual Weight$1,360.00 ➝ $1,000.00
11/6/2020WedbushLower TargetOutperform$1,620.00 ➝ $1,460.00
11/5/2020Stifel NicolausDowngradeBuy ➝ Hold$1,540.00 ➝ $1,020.00
11/5/2020BarclaysDowngradeOverweight ➝ Equal Weight
11/5/2020JPMorgan Chase & Co.Lower TargetOverweight$2,800.00 ➝ $1,520.00
11/5/2020Wells Fargo & CompanyLower TargetOverweight$1,880.00 ➝ $1,620.00
11/5/2020Leerink PartnersLower TargetOutperform$2,660.00 ➝ $1,980.00
11/5/2020Bank of AmericaLower TargetBuy$2,000.00 ➝ $1,620.00
11/5/2020Royal Bank of CanadaLower TargetOutperform$2,000.00 ➝ $1,860.00
11/5/2020OppenheimerLower TargetOutperform$2,220.00 ➝ $1,800.00
11/5/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$2,160.00 ➝ $1,120.00
11/4/2020Piper SandlerLower TargetNeutral$1,400.00 ➝ $1,100.00
11/2/2020William BlairUpgradeMarket Perform ➝ Outperform
10/19/2020MizuhoInitiated CoverageBuy$2,460.00
8/31/2020OppenheimerInitiated CoverageBuy$2,220.00
8/30/2020William BlairReiterated RatingHold
8/19/2020JPMorgan Chase & Co.Reiterated RatingBuy
8/10/2020Morgan StanleyLower TargetEqual Weight$1,460.00 ➝ $1,360.00
8/6/2020BMO Capital MarketsLower TargetOutperform$2,240.00 ➝ $2,160.00
8/6/2020WedbushLower TargetOutperform$1,780.00 ➝ $1,620.00
7/29/2020OppenheimerInitiated CoverageBuy$2,220.00
7/13/2020Bank of AmericaLower TargetBuy$2,080.00 ➝ $2,000.00
6/12/2020Leerink PartnersBoost TargetOutperform$2,580.00 ➝ $2,660.00
6/1/2020OppenheimerInitiated CoverageBuy$2,220.00
5/28/2020Morgan StanleyBoost TargetEqual Weight$1,380.00 ➝ $1,460.00
5/28/2020Leerink PartnersBoost TargetOutperform$2,500.00 ➝ $2,580.00
5/17/2020OppenheimerInitiated CoverageBuy$2,220.00
5/13/2020BarclaysReiterated RatingBuy
5/12/2020Royal Bank of CanadaInitiated CoverageOutperform$2,000.00
5/12/2020BMO Capital MarketsBoost TargetOutperform$2,140.00 ➝ $2,240.00
5/11/2020OppenheimerInitiated CoverageBuy$2,440.00 ➝ $2,220.00
5/11/2020Piper SandlerLower TargetNeutral$1,500.00 ➝ $1,400.00
4/15/2020Morgan StanleyLower TargetEqual Weight$1,840.00 ➝ $1,380.00
3/27/2020BMO Capital MarketsLower TargetOutperform$2,640.00 ➝ $2,140.00
3/27/2020William BlairReiterated RatingHold
3/26/2020Stifel NicolausUpgradeHold ➝ Buy$1,880.00 ➝ $1,400.00
3/26/2020Piper SandlerLower Target$1,700.00 ➝ $1,500.00
3/26/2020Wells Fargo & CompanyReiterated RatingBuy
2/26/2020Morgan StanleyLower TargetEqual Weight$2,000.00 ➝ $1,840.00
2/20/2020OppenheimerLower Target$2,700.00 ➝ $2,560.00
2/19/2020Raymond JamesDowngradeStrong-Buy ➝ Market Perform
2/19/2020Stifel NicolausLower TargetHold$1,920.00 ➝ $1,880.00
2/3/2020Bank of AmericaInitiated CoverageBuy$2,400.00
2/3/2020Evercore ISIUpgradeIn-Line ➝ Outperform$1,720.00 ➝ $2,000.00
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 43 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 8 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 4 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
10/22/2024
  • 2 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 2 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 2 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

bluebird bio logo
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
Read More

Today's Range

Now: $8.50
Low: $7.94
High: $9.80

50 Day Range

MA: $8.53
Low: $5.89
High: $14.73

52 Week Range

Now: $8.50
Low: $5.80
High: $38.40

Volume

899,239 shs

Average Volume

398,183 shs

Market Capitalization

$82.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Frequently Asked Questions

What sell-side analysts currently cover shares of bluebird bio?

The following Wall Street sell-side analysts have issued stock ratings on bluebird bio in the last twelve months: Bank of America Co., Barclays PLC, Cantor Fitzgerald, HSBC Holdings plc, JPMorgan Chase & Co., Robert W. Baird, Royal Bank of Canada, StockNews.com, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for BLUE.

What is the current price target for bluebird bio?

0 Wall Street analysts have set twelve-month price targets for bluebird bio in the last year. Their average twelve-month price target is $49.14, suggesting a possible upside of 478.2%. Robert W. Baird has the highest price target set, predicting BLUE will reach $120.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $10.00 for bluebird bio in the next year.
View the latest price targets for BLUE.

What is the current consensus analyst rating for bluebird bio?

bluebird bio currently has 2 sell ratings, 6 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BLUE, but not buy more shares or sell existing shares.
View the latest ratings for BLUE.

What other companies compete with bluebird bio?

Other companies that are similar to bluebird bio include Krystal Biotech, Arcellx, ADMA Biologics, Immunovant and Scholar Rock. Learn More about companies similar to bluebird bio.

How do I contact bluebird bio's investor relations team?

bluebird bio's physical mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (339) 499-9300 and its investor relations email address is [email protected]. The official website for bluebird bio is www.bluebirdbio.com. Learn More about contacing bluebird bio investor relations.